Is TB-500 Legal in Minnesota? Federal Law, State Rules, and How to Get It

HealthRX.com

TB-500 has no approved legal route in Minnesota yet

Print or save as PDF

See the public record for TB-500

  • FDA approval / None; no approved drug contains TB-500 [1]
  • FDA compounding lists / In none of the three categories on FDA's pharmacy bulk-substance list and absent from the outsourcing-facility list; the category 1 policy does not cover it [2][3][6]
  • FDA safety-risk page / In the nominated but withdrawn table, not the active category 2 table [7]
  • July 2026 advisory vote / Committee favored adding it; advice only, not binding [8][4]
  • HHS October 2026 policy / Draft enforcement discretion for TB-500 acetate by injection; not final [4][5]
  • Human studies / None found in which TB-500 was given to a person [1]
  • Sport / Prohibited at all times by WADA [9]

Why TB-500 is not simply legal

TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, and no FDA-approved drug contains it. FDA found no USP or National Formulary monograph for it [1]. Under federal compounding rules, a state-licensed pharmacy may use a bulk substance only if an applicable USP or National Formulary monograph exists, the substance is a component of an FDA-approved drug, or it appears on FDA's bulk-substance list for those pharmacies [6]. TB-500 meets none of those conditions [1][2][6].

It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026). It is likewise absent from FDA's list for outsourcing facilities (updated March 21, 2025), and the category 1 policy does not cover it [2][3][6]. FDA lists it in the nominated but withdrawn table of its safety-risk page rather than the active category 2 table, and removal from category 2 was not a finding of safety [7]. FDA's stated concerns are missing human exposure data, missing safety information, and immunogenicity risk from aggregation and peptide-related impurities in injectable peptides [7].

What people on Reddit report

Reddit comments from a discussion of a recent FDA committee vote. The accounts range from a pharmacy owner describing state board guidance to patients asking whether their clinic's setup is legal.

Rockinvestor · NTNPerformance

Speaking to my state board, they said providers can prescribe any peptide therapy they want as off label use, but the pharmacies are not allowed to compound them.

A pharmacy owner reports that their state board said prescribers may use peptides off label, but pharmacies may not compound them.

Read the source discussion

strange_waters · NTNPerformance

I go to a wellness clinic that specializes in peptides and the doctor actually prescribes them to be compounded in a verified 503a Pharmacy. I thought that as of right now, there was kind of a grey area in the system that allows for pharmacies and doctors to do that and it's not actually illegal.

A patient whose clinic uses a compounding pharmacy asks whether that arrangement is legitimate, since they thought it was a gray area.

Read the source discussion

dignan2002 · NTNPerformance

I'm super excited. Like you said, it's an advisory committee vote so the fda might just slap it down, but it's a step in the right direction.

A commenter is hopeful about the vote but notes it is only advisory and FDA could still reject it.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

The July 2026 advisory vote

FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 on July 23, 2026 and voted in favor of adding it to the bulks list, against FDA staff's recommendation. The vote is advice only, TB-500 is not on the list, and adding it takes formal rulemaking [8][4]. FDA staff had proposed that neither the free base nor the acetate be added. They cited inconsistent naming, no impurity, aggregate or endotoxin data, no human data of any kind, and immunogenicity risk [1].

Dr Ashley Froese on why the FDA vote may not fix the gray market

Dr. Ashley Froese argues that the upcoming FDA advisory committee meeting will not fix the gray market for peptides. She says the review asks whether the evidence supports specific medical uses, not whether the peptides work, and that doctors can still prescribe an approved ingredient off-label. On thymosin beta four, she describes it as a cell-building protein that guides cells to an injury site, which is why people use it for wound healing and joint pain. She is skeptical that a vote will stop research peptide websites or telehealth startups, saying the horse has already left the barn. She closes by asking viewers what they think.

Who is speaking?

Dr. Ashley Froese. Doctor and YouTube host, as described on the channel Background

Episode notes and full video

The October 2026 HHS draft

HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192, publication scheduled October 30, 2026). It names TB-500 among six peptides and covers TB-500 acetate by subcutaneous or intramuscular injection [4][5]. Its conditions include a single active ingredient, a patient-specific prescription and an FDA-registered manufacturer with a certificate of analysis [5]. The notice says it establishes no rights for any person, is not binding on HHS or the public, and may be revisited [4]. It does not put TB-500 on any list [4].

Availability and sport

These federal rules apply to pharmacies and physicians in Minnesota as in other states. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].

WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times in and out of competition. It is on the 2026 List and stays on the 2027 List [9][10].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what form of TB-500 does the HHS draft policy cover?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is TB-500 legal in Minnesota?
TB-500 is not FDA-approved and is in none of the categories on FDA's compounding lists for pharmacies and outsourcing facilities. The only policy naming it for compounded use is a draft HHS enforcement-discretion policy covering TB-500 acetate by injection, which is not final or binding [1][2][3][4][5].
Can a pharmacy compound TB-500 now?
Not under FDA's existing pharmacy compounding rules. TB-500 has no USP or National Formulary monograph, is not a component of an FDA-approved drug, is not on FDA's bulk-substance list for state-licensed pharmacies, and the category 1 policy does not cover it [1][2][6]. The HHS draft says it does not intend to take enforcement action if its conditions are met, but it is not final and not binding [4][5]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
Did the advisory committee vote make TB-500 compoundable?
No. The Pharmacy Compounding Advisory Committee voted in favor of adding it to the bulks list on July 23, 2026, against FDA staff's recommendation, but that is non-binding advice, TB-500 is not on the list, and adding it takes formal rulemaking [8][4].
Has TB-500 been tested in people?
FDA searched PubMed, Embase, ClinicalTrials.gov and other sources and found no article in which TB-500 was given to a human, and none of the three papers the nominator cited involved TB-500 in humans [1].
Is TB-500 banned in sport?
WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times in and out of competition, and it stays on the 2027 List [9][10].
Show all 12 referencesHide references
Evidence overview for Is TB-500 Legal in Minnesota? Federal Law, State Rules, and How to Get It